| Microbiota Transplant to Cancer Patients Who Have Failed Immunotherapy Using Faeces From Clinical Responders (NCT05286294) | Oslo University Hospital | 2022-06-28 |
| Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma (NCT05433142) | Xencor, Inc. | 2022-06-13 |
| 68Ga-P16-093 and 18F-FDG PET/CT Imaging in the Same Group of Clear Cell Renal Cell Carcinoma Patients (NCT05432947) | Peking Union Medical College Hospital | 2022-04-14 |
| A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) (NCT05121948) | HiberCell, Inc. | 2022-02-23 |
| Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer (NCT05239533) | Memorial Sloan Kettering Cancer Center | 2022-02-16 |
| Novel Biomarkers of Hypoxia and Metabolism in Clear Cell Renal Cell Carcinoma (NCT05214885) | Qianfoshan Hospital | 2022-02-11 |
| A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies (NCT05199272) | 23andMe, Inc. | 2021-12-29 |
| A Small-molecule Carbonic Anhydrase IX Targeting PET Tracer in Clear Cell Renal Cell Carcinoma (NCT05728515) | Peking Union Medical College Hospital | 2021-12-25 |
| A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma (NCT05119335) | NiKang Therapeutics, Inc. | 2021-10-26 |
| A Beta-only IL-2 ImmunoTherapY Study (NCT05086692) | Medicenna Therapeutics, Inc. | 2021-08-27 |
| Pembrolizumab and Axitinib as Neoadjuvant Therapy for Locally Advanced Non-metastatic Clear Cell Renal Cell Carcinoma (NCT04995016) | Tianjin Medical University Second Hospital | 2021-08-20 |
| [18F]PT2385 PET/CT in Patients With Renal Cell Carcinoma (NCT04989959) | Orhan Kemal Oz | 2021-08-18 |
| A Study of Sintilimab in Combination With Axitinib in Advanced Renal Cell Cancer (NCT04958473) | Tianjin Medical University Second Hospital | 2021-08-01 |
| A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread (NCT04810078) | Bristol-Myers Squibb | 2021-05-21 |
| Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (NCT04779151) | Gustave Roussy, Cancer Campus, Grand Paris | 2021-04-07 |
| Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma (NCT04300140) | Aravive, Inc. | 2021-02-26 |
| Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery (NCT04370509) | University of California, San Francisco | 2021-02-09 |
| Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma (NCT04169711) | Arrowhead Pharmaceuticals | 2020-08-17 |
| Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies (NCT04518046) | Mirati Therapeutics Inc. | 2020-08-11 |
| Evaluation of Safety, Biodistibution and Sensitivity/Specificity of PET/CT Imaging With 89Zr-TLX250 in Subjects With RCC (NCT04496089) | Telix Pharmaceuticals (Innovations) Pty Limited | 2020-08-01 |
| Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study (NCT04071223) | National Cancer Institute (NCI) | 2020-07-29 |
| Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors (NCT04374877) | Coherus Oncology, Inc. | 2020-04-22 |
| Evaluation of Urinary Exosomes Presence From Clear Cell Renal Cell Carcinoma (NCT04053855) | Centre Hospitalier Universitaire de Saint Etienne | 2020-01-29 |
| AURORAX-0087A: GAG Scores for Surveillance of Recurrence in Leibovich Points ≥5 Non-metastatic ccRCC (NCT04006405) | Elypta | 2020-01-10 |
| 89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study (NCT03849118) | Telix Pharmaceuticals (Innovations) Pty Limited | 2019-08-15 |
| Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer (NCT04022343) | Emory University | 2019-08-06 |
| Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study (NCT03793166) | National Cancer Institute (NCI) | 2019-06-07 |
| Study of PD-1 Inhibitor Combination With Autologous Cell Immunotherapy in the Metastatic Renal Cell Carcinoma (NCT03987698) | Tianjin Medical University Cancer Institute and Hospital | 2019-06-01 |
| Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors (NCT03875313) | Calithera Biosciences, Inc | 2019-05-20 |
| CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer (NCT03829111) | City of Hope Medical Center | 2019-05-14 |
| Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2 (NCT03284385) | National Cancer Institute (NCI) | 2019-01-29 |
| Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors (NCT03682289) | Rahul Aggarwal | 2019-01-17 |
| Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma (NCT03680521) | Mirati Therapeutics Inc. | 2018-10-10 |
| Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing In Blood and Urine, The INQUIRE Study (NCT06339138) | Mayo Clinic | 2018-06-27 |
| Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer (NCT03473730) | M.D. Anderson Cancer Center | 2018-05-29 |
| Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab (NCT03149159) | Medical University of South Carolina | 2018-04-01 |
| Prior Axitinib as a Determinant of Outcome of Renal Surgery (NCT03438708) | University of California, San Diego | 2018-03-05 |
| Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery (NCT03334409) | Academic and Community Cancer Research United | 2018-02-16 |
| Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer (NCT03308396) | Ajjai Alva, MD | 2017-12-19 |
| Biomarker Study of Pts With Metastatic ccRCC Undergoing Sequential Therapy With 1st Line Sunitinib and 2nd Line Axitinib (NCT03592199) | Instituto do Cancer do Estado de São Paulo | 2017-12-11 |
| Enzalutamide Before Surgery in Treating Patients With Kidney Cancer (NCT02885649) | Rutgers, The State University of New Jersey | 2017-12-05 |
| CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC) (NCT03163667) | Calithera Biosciences, Inc | 2017-09-06 |
| Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer (NCT03092856) | University of Southern California | 2017-07-19 |
| Diagnostic Imaging for Clear Cell Renal Cell Carcinoma (NCT03185182) | Region Skane | 2017-07-14 |
| Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma (NCT03035630) | Guru Sonpavde | 2017-05-23 |
| Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors (NCT02581384) | Dana-Farber Cancer Institute | 2017-01-01 |
| Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma (NCT02923531) | X4 Pharmaceuticals | 2016-12-07 |
| A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001) (NCT02974738) | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2016-12-07 |
| A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma (NCT02837991) | Celldex Therapeutics | 2016-06-01 |
| Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA (NCT02607553) | GenSpera, Inc. | 2016-06-01 |
| Nivolumab in Treating Patients With High-Risk Kidney Cancer Before Surgery (NCT02595918) | National Cancer Institute (NCI) | 2016-05-19 |
| Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma (NCT02667886) | X4 Pharmaceuticals | 2016-04-27 |
| Tremelimumab With or Without Cryoablation in Treating Patients With Metastatic Kidney Cancer (NCT02626130) | M.D. Anderson Cancer Center | 2016-03-30 |
| Study of Neoadjuvant Nivolumab in Patients With Non-metastatic Stage II-IV Clear Cell Renal Cell Carcinoma (NCT02575222) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2016-02-01 |
| Axitinib in Metastatic Renal Cell Carcinoma Patients With Favorable Prognostic Factors (NCT02700568) | Kidney Cancer Research Bureau | 2016-01-01 |
| Safety Study of MGD009 in B7-H3-expressing Tumors (NCT02628535) | MacroGenics | 2015-09-01 |
| A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell Cancer (NCT02307474) | Case Comprehensive Cancer Center | 2015-09-01 |
| Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors (NCT02496208) | National Cancer Institute (NCI) | 2015-07-22 |
| Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery (NCT02210117) | M.D. Anderson Cancer Center | 2014-11-25 |
| A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001) (NCT02293980) | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2014-11-25 |
| A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies (NCT02118337) | MedImmune LLC | 2014-05-19 |
| Stereotactic Body Radiation Therapy and T-Cell Infusion in Treating Patients With Metastatic Kidney Cancer (NCT01943188) | Stanford University | 2014-05-01 |
| Value of Various Chemokines in the Detection and Follow up of RCC (NCT02022787) | Carmel Medical Center | 2014-01-01 |
| Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer (NCT01835158) | National Cancer Institute (NCI) | 2013-07-08 |
| Autologous Dendritic Cells in Treating Patients With Metastatic Kidney Cancer (NCT01826877) | Jonsson Comprehensive Cancer Center | 2013-01-14 |
| Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer (NCT01684397) | Roswell Park Cancer Institute | 2012-11-21 |
| Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer (NCT01727089) | National Cancer Institute (NCI) | 2012-11-01 |
| Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery (NCT01575548) | National Cancer Institute (NCI) | 2012-08-08 |
| Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib Hydrochloride in Patients With Metastatic Kidney Cancer (NCT01599832) | University of Chicago | 2012-06-01 |
| 1st-line Activity of Dovitinib and Correlation With Genetic Changes in RCC (NCT01791387) | Auckland District Health Board | 2012-03-01 |
| AMG 172 First in Human Study in Patients With Kidney Cancer (NCT01497821) | Amgen | 2012-01-01 |
| Investigating Patient Satisfaction With Oral Anti-Cancer Treatment (NCT02247583) | KU Leuven | 2011-02-01 |
| Pazopanib Hydrochloride in Treating Patients With Stage IV Kidney Cancer (NCT01157091) | City of Hope Medical Center | 2010-12-08 |
| Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies (NCT01243359) | National Cancer Institute (NCI) | 2010-10-01 |
| Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy (NCT01198158) | National Cancer Institute (NCI) | 2010-09-15 |
| Sunitinib Malate in Treating Patients With Previously Untreated Metastatic Kidney Cancer (NCT01158222) | Case Comprehensive Cancer Center | 2010-08-18 |
| Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer (NCT01158521) | Case Comprehensive Cancer Center | 2010-06-01 |
| A Study of RO4929097 in Patients With Advanced Renal Cell Carcinoma That Have Failed Vascular Endothelial Growth Factor (VEGF)/Vascular Endothelial Growth Factor Receptor (VEGFR) Therapy (NCT01141569) | National Cancer Institute (NCI) | 2010-06-01 |
| Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate (NCT01582009) | Roswell Park Cancer Institute | 2010-03-01 |
| Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer (NCT01038778) | National Cancer Institute (NCI) | 2009-10-29 |
| Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy (NCT00890747) | National Cancer Institute (NCI) | 2009-08-01 |
| Neoadjuvant Sunitinib Treatment for Metastatic Clear Cell Renal Cell Carcinoma (RCC) (NCT01069770) | Korean Urological Oncology Society | 2009-07-01 |
| Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer (NCT00378703) | National Cancer Institute (NCI) | 2007-09-14 |
| Effect of Sorafenib on ccRCC Uptake of Radiolabeled Bevacizumab or cG250 (NCT00602862) | Radboud University Medical Center | 2007-07-01 |
| Sunitinib Malate in Treating Patients With Unresectable or Metastatic Kidney Cancer or Other Advanced Solid Tumors (NCT00499135) | National Cancer Institute (NCI) | 2007-05-22 |
| Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney Cancer (NCT00408902) | National Cancer Institute (NCI) | 2006-11-01 |
| Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors (NCT00335556) | Children's Oncology Group | 2006-06-01 |
| Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery (NCT00326898) | National Cancer Institute (NCI) | 2006-04-24 |
| AZD2171 in Treating Patients With Refractory Metastatic Kidney Cancer (NCT00303862) | National Cancer Institute (NCI) | 2006-03-01 |
| Vorinostat and Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer (NCT00324870) | National Cancer Institute (NCI) | 2006-02-01 |
| Ixabepilone in Treating Patients With Metastatic, Recurrent, or Unresectable Kidney Cancer (NCT00182702) | National Cancer Institute (NCI) | 2005-07-01 |
| Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer (NCT00126594) | National Cancer Institute (NCI) | 2005-06-01 |
| Safety Study With the Antibody, cG250, and Isotope, 124-Iodine, to Diagnose Patients With Renal Masses. (NCT00199888) | Ludwig Institute for Cancer Research | 2005-06-01 |
| Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer (NCT00126503) | National Cancer Institute (NCI) | 2005-05-01 |
| CCI-779 and Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney Cancer (NCT00112840) | National Cancer Institute (NCI) | 2005-05-01 |
| Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer (NCT00098618) | National Cancer Institute (NCI) | 2004-10-01 |
| Sorafenib and Interferon Alfa in Treating Patients With Metastatic or Unresectable Kidney Cancer (NCT00101114) | National Cancer Institute (NCI) | 2004-09-01 |
| Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma (NCT00193258) | SCRI Development Innovations, LLC | 2004-06-01 |
| Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant (NCT00078858) | Fred Hutchinson Cancer Center | 2003-09-01 |
| Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer (NCT00027820) | Fred Hutchinson Cancer Center | 2001-08-01 |